IP Library Granted Patent US 9,260,710
Granted Patent B2
US 9,260,710 · App. 14/754,064 · Granted Feb 16, 2016

Photocleavable linker

Inventors: John C. Williams (Duarte, CA); David Horne (Duarte, CA); Jun Xie (Duarte, CA); Shubbir Ahmed (Duarte, CA)
Assignee: City of Hope
C12N9/90C07D211/60G01N33/5023C12Y502/01G01N2333/4703G01N2333/914
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,260,710
App. No.
14/754,064
Granted
Feb 16, 2016
Kind
B2
Abstract

There are provided, inter alia, photolabile compounds and methods useful for the formation of dimers of biological molecules and subsequent dissociation of the dimers.

Claims (34)

1. A method for forming a FK506 binding protein (FKBP) dimer, wherein each FKBP of the dimer is fused to a peptide, said method comprising:

(i) contacting a first FKBP fused to a peptide and a second FKBP fused to a peptide with a compound of Formula (I); and

(ii) allowing said compound to bind to said first FKBP fused to a peptide and said second FKBP fused to a peptide, thereby forming said FKBP dimer comprising a link between said first FKBP fused to a peptide and said second FKBP fused to a peptide;

thereby forming a FKBP dimer, wherein each FKBP of the dimer is fused to a peptide;

wherein,

said compound of Formula (I) has the structure

wherein,

L 1 is a photocleavable linker, and

z 1 and z 2 are each independently an integer in the range 0 to 6.

2. The method of claim 1 , wherein L 1 is substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene.

3. The method of claim 1 , wherein L 1 comprises a nitrophenylene.

4. The method of claim 1 , wherein said peptide is selected from the group consisting of a dynein intermediate chain (IC) peptide, a fragment of IC peptide, an analog of IC peptide, a dynein intermediate chain IC2C peptide, a fragment of dynein intermediate chain IC2C peptide, and an analog of dynein intermediate chain IC2C peptide.

5. The method of claim 4 , wherein said peptide is an IC peptide, or fragment or analog thereof.

6. The method of claim 5 , wherein said peptide binds LC8.

7. The method of claim 4 , wherein said peptide is an dynein intermediate chain IC2C peptide, or fragment or analog thereof.

8. The method of claim 7 , wherein said peptide binds TcTex1.

9. The method of claim 1 , wherein said first FKBP fused to a peptide and said second FKBP fused to a peptide further comprise a reporter group.

10. The method of claim 9 , wherein said reporter group is a dye, a radioactive moiety, or a protein.

11. A method for antagonizing a dynein-associated process in a cell, said method comprising:

(i) contacting a cell with the FK506 binding protein (FKBP) dimer of claim 1 under conditions suitable to antagonize a dynein-associated process.

12. The method of claim 11 , further comprising:

(ii) monitoring a dynein-associated process in said cell.

13. The method of claim 12 , wherein said monitoring monitors endosome dispersion, lysosome dispersion or Golgi dispersion.

14. The method of claim 13 , wherein said endosome dispersion is increased, lysosome dispersion is increased, or Golgi dispersion is increased.

15. The method of claim 13 , wherein endosome dispersion is monitored by assaying the level of early endosome markers 1 (EEA1).

16. The method of claim 13 , wherein Golgi dispersion is monitored by assaying the level of GM130 marker.

17. The method of claim 12 , further comprising

(iii) contacting said cell with light under conditions suitable to afford photocleavage of said compound of claim 1 .

18. The method of claim 12 , wherein said dynein-associated process is a cytoplasmic dynein function distinct from vesicular transport.

19. The method of claim 18 , said cytoplasmic dynein function is mitotic behavior.

20. A method for synthesizing a compound of Formula (IV):

said method comprising contacting a compound with structure of Formula (5)

 with diol 6,

under conditions suitable to afford the compound of Formula (IV).

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 3, 2015
From: CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 037035/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2015
From: WILLIAMS, JOHN C.; HORNE, DAVID; XIE, JUN; AHMED, SHUBBIR
To: CITY OF HOPE
Reel/Frame 036313/0350 →
Continuity (3)
Continuation 14083938 · Nov 19, 2013
Provisional Application 61728138 · Nov 19, 2012
Related Publication 20150291950A1 · Oct 15, 2015